PMID- 37717622
OWN - NLM
STAT- MEDLINE
DCOM- 20231011
LR  - 20231011
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 332
DP  - 2023 Nov 1
TI  - Combination chemotherapy against colorectal cancer cells: Co-delivery of 
      capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene 
      glycol carriers.
PG  - 122083
LID - S0024-3205(23)00718-X [pii]
LID - 10.1016/j.lfs.2023.122083 [doi]
AB  - BACKGROUND: Colorectal cancer causes numerous deaths despite many treatment 
      options. Capecitabine (CAP) is the standard chemotherapy regimen for colorectal 
      cancer, and pioglitazone hydrochloride (PGZ) for diabetic disease treatment. 
      However, free drugs do not induce effective apoptosis. This work aims to 
      co-encapsulate CAP and PGZ and evaluate cytotoxic and apoptotic effects on 
      HCT-119, HT-29 colorectal cancer cells, and human umbilical vein endothelial 
      cells (HUVECs). METHOD: CAP, PGZ, and combination treatment nano-formulations 
      were prepared by triblock (TB) (PCL-PEG-PCL) biodegradable copolymers to enhance 
      drugs' bioavailability as anti-cancer agents. The Ultrasonic homogenization 
      method was used for preparing nanoparticles. The physicochemical characteristics 
      of nanoparticles were studied using (1)H NMR, FTIR, DLS, and FESEM techniques. 
      The zeta potential, entrapment efficiency, drug release, and storage stability 
      were studied. Also, cell viability and apoptosis were examined by using MTT, 
      acridine orange (AO), and propidium iodide (PI), respectively. RESULT: The 
      smaller hydrodynamic size (236.1 nm), polydispersity index (0.159), and zeta 
      potential (-20.8 mV) were observed in nanoparticles. Nanoparticles revealed a 
      proper formulation and storage stability at 25  degrees C than 4  degrees C in 90 days. The 
      synergistic effect was observed in (CAP-PGZ)-loaded TB nanoparticles in HUVEC, 
      HCT-116, and HT-29 cells. In (AO/PI) staining, the high percentage of apoptotic 
      cells in the (CAP-PGZ)-loaded TB nanoparticles in HUVEC, HCT-116, and HT-29 were 
      calculated as 78 %, 71.66 %, and 69.31 %, respectively. CONCLUSION: The 
      (CAP-PGZ)-loaded TB nanoparticles in this research offer an effective strategy 
      for targeted combinational colorectal cancer therapy.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Pouya, Fahima Danesh
AU  - Pouya FD
AD  - Department of Biochemistry, Faculty of Medicine, Urmia University of Medical 
      Sciences, Urmia, Iran. Electronic address: daneshpouya.f@umsu.ac.ir.
FAU - Salehi, Roya
AU  - Salehi R
AD  - Department of Medical Nanotechnology, Drug Applied Research Center, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Rasmi, Yousef
AU  - Rasmi Y
AD  - Department of Biochemistry, Faculty of Medicine, Urmia University of Medical 
      Sciences, Urmia, Iran; Cellular and Molecular Research Center, Cellular and 
      Molecular Medicine Research Institute, Urmia University of Medical Sciences, 
      Urmia, Iran. Electronic address: rasmiy@umsu.ac.ir.
FAU - Kheradmand, Fatemeh
AU  - Kheradmand F
AD  - Department of Biochemistry, Faculty of Medicine, Urmia University of Medical 
      Sciences, Urmia, Iran.
FAU - Fathi-Azarbayjani, Anahita
AU  - Fathi-Azarbayjani A
AD  - Department of Pharmaceutical Sciences, Faculty of Pharmacy, Urmia University of 
      Medical Sciences, Urmia, Iran.
LA  - eng
PT  - Journal Article
DEP - 20230917
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - X4OV71U42S (Pioglitazone)
RN  - 24980-41-4 (polycaprolactone)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - 0 (Antineoplastic Agents)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
SB  - IM
MH  - Humans
MH  - Pioglitazone/pharmacology
MH  - Capecitabine/pharmacology
MH  - *Antineoplastic Agents
MH  - Human Umbilical Vein Endothelial Cells
MH  - Polyethylene Glycols/chemistry
MH  - *Colorectal Neoplasms/drug therapy
MH  - Drug Therapy, Combination
OTO - NOTNLM
OT  - Apoptosis
OT  - Capecitabine
OT  - Colorectal cancer
OT  - Combination chemotherapy
OT  - Micelle
OT  - Pioglitazone hydrochloride
COIS- Declaration of competing interest The authors declare that there are no conflicts 
      of interest.
EDAT- 2023/09/18 00:41
MHDA- 2023/10/11 06:45
CRDT- 2023/09/17 19:13
PHST- 2023/07/08 00:00 [received]
PHST- 2023/09/01 00:00 [revised]
PHST- 2023/09/11 00:00 [accepted]
PHST- 2023/10/11 06:45 [medline]
PHST- 2023/09/18 00:41 [pubmed]
PHST- 2023/09/17 19:13 [entrez]
AID - S0024-3205(23)00718-X [pii]
AID - 10.1016/j.lfs.2023.122083 [doi]
PST - ppublish
SO  - Life Sci. 2023 Nov 1;332:122083. doi: 10.1016/j.lfs.2023.122083. Epub 2023 Sep 
      17.